INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
86.92
-1.78 (-2.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close88.70
Open88.70
Bid0.00 x 900
Ask0.00 x 800
Day's Range86.67 - 89.30
52 Week Range57.00 - 89.30
Volume1,272,512
Avg. Volume1,348,957
Market Cap18.639B
Beta (3Y Monthly)1.01
PE Ratio (TTM)74.80
EPS (TTM)1.16
Earnings DateJul 29, 2019 - Aug 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.06
Trade prices are not sourced from all markets
  • This would be the worst-case scenario for health stocks, according to UBS
    MarketWatch3 days ago

    This would be the worst-case scenario for health stocks, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.

  • The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

  • Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
    Zacks6 days ago

    Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

    A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

  • Merck's Keytruda Gets 2nd Label Expansion Approval in June
    Zacks6 days ago

    Merck's Keytruda Gets 2nd Label Expansion Approval in June

    Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.

  • TheStreet.com6 days ago

    2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

    "Merger Monday" finally lived up to its billing this week in Biotech Land. announced just before the opening bell Monday that it was acquiring oncology concern Array Biopharma Inc. Pfizer paid a buyout premium of more than 60% to purchase Array.

  • Cancer Therapy Stocks Soar After Pfizer Deal
    Investopedia7 days ago

    Cancer Therapy Stocks Soar After Pfizer Deal

    Cancer therapy stocks rallied after Pfizer made a deal to boost its oncology offerings. These industry players may also be takeover targets.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold INCY had net inflows of $2.58 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
    MarketWatch7 days ago

    Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

    Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.

  • Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up
    Investor's Business Daily8 days ago

    Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up

    Bitcoin trading was active again Monday amid a solid gain for the Nasdaq. The tech-laden index was helped by strength in software and biotech stocks.

  • 2 Rallying Pharma Stocks Roping In Option Bulls
    Schaeffer's Investment Research8 days ago

    2 Rallying Pharma Stocks Roping In Option Bulls

    Short sellers could be shaking in their boots

  • Business Wire10 days ago

    Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

    Incyte (INCY) today announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients (18 to 75 years of age) with vitiligo. The study met its primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream for 24 weeks achieved a ≥50 percent improvement from baseline in the facial vitiligo area severity index (F-VASI50) score compared to patients treated with a vehicle control (non-medicated cream).

  • Here’s What Hedge Funds Think About Incyte Corporation (INCY)
    Insider Monkey11 days ago

    Here’s What Hedge Funds Think About Incyte Corporation (INCY)

    Is Incyte Corporation (NASDAQ:INCY) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]

  • Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
    Zacks12 days ago

    Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I

    Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.

  • Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
    Zacks12 days ago

    Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock

    Here are five reasons why investors may consider betting on Merck (MRK) stock

  • Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
    Zacks12 days ago

    Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study

    Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.

  • Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
    Zacks13 days ago

    Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer

    Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.

  • American City Business Journals18 days ago

    9 interesting things heard during BIO 2019 (Photos)

    Philadelphia’s fourth turn hosting the Biotechnology Innovation Organization’s annual international conference concluded Thursday. The BIO 2019 event featured a variety of panel discussions, keynote interviews, fireside chats and company presentations, covering a myriad of topics in the life sciences industry.

  • Incyte Begins Phase III Study for Treatment of Duct Cancer
    Zacks19 days ago

    Incyte Begins Phase III Study for Treatment of Duct Cancer

    Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.

  • Celgene (CELG) Presents Data on Pipeline Candidates at ASCO
    Zacks20 days ago

    Celgene (CELG) Presents Data on Pipeline Candidates at ASCO

    Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.

  • Investor's Business Daily21 days ago

    Looking For Growth? Take A Look At These Biotechnology Stocks

    The best biotech companies to invest in tend to have a commonality: A strong streak of earnings growth.

  • Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend — traders to sell the rally
    Yahoo Finance Video18 days ago

    Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend — traders to sell the rally

    Joining Yahoo Finance's Jen Rogers and Myles Udland is Jared Blikre to break down the week's market action in the S&P 500, its 11 sectors (where tech is leading the year again), as well as the weekly winners in the Nasdaq 100 — all with the help of our new YFi Interactive touch screen.